The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Official Title: The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Study ID: NCT00224562
Brief Summary: The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.
Detailed Description:
Minimum Age: 0 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
All French departments of rheumatology, internal medicine, gastro-enterology, dermatology, infectious diseases, intensive care unit, oncology and haematology, paediatrics and chest medicine, All Cities, , France
Name: Xavier Mariette, MD PhD
Affiliation: Assistance Publique - H么pitaux de Paris
Role: PRINCIPAL_INVESTIGATOR
Name: Dominique Salmon, MD
Affiliation: Assistance Publique - H么pitaux de Paris
Role: PRINCIPAL_INVESTIGATOR
Name: Marc Lemann, MD
Affiliation: Assistance Publique - H么pitaux de Paris
Role: PRINCIPAL_INVESTIGATOR